{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:26Z","timestamp":1787009006462,"version":"build-2736575974"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of patients coinfected with hepatitis C and human immunodeficiency viruses (HCV; HIV) requires careful consideration of potential drug-drug interactions between HCV direct-acting antiviral agents (DAA) and HIV antiretrovirals. Glecaprevir\/pibrentasvir is a fixed-dose combination of an NS3\/4A protease inhibitor and an NS5A inhibitor approved for the treatment of chronic HCV genotype 1\u20136 infection, including patients with HIV coinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A series of phase 1 studies was conducted to evaluate potential interactions of glecaprevir and pibrentasvir with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide, abacavir\/dolutegravir\/lamivudine, raltegravir, rilpivirine, atazanavir\/ritonavir, darunavir\/ritonavir, lopinavir\/ritonavir, or efavirenz\/emtricitabine\/tenofovir disoproxil fumarate. Pharmacokinetics of the antiretrovirals and DAAs were characterized when administered alone and in combination to quantify changes in systemic drug exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Glecaprevir area under the curve increased &amp;gt;4-fold in the presence of ritonavir-boosted HIV protease inhibitors, while pibrentasvir concentrations were not significantly affected; elevations in alanine transaminase occurred in combination with atazanavir\/ritonavir only. Exposures of glecaprevir and pibrentasvir may be significantly decreased by efavirenz. Coadministration with glecaprevir and pibrentasvir did not result in clinically significant changes in the exposure of any antiretroviral agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Atazanavir is contraindicated with glecaprevir\/pibrentasvir and use of boosted protease inhibitors or efavirenz is not recommended. No clinically significant interactions were observed with other studied antiretrovirals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiz439","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T07:39:55Z","timestamp":1566977995000},"page":"223-231","source":"Crossref","is-referenced-by-count":19,"title":["Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals"],"prefix":"10.1093","volume":"221","author":[{"given":"Matthew P","family":"Kosloski","sequence":"first","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneet","family":"Oberoi","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wang","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando M","family":"Viani","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Hu","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bifeng","family":"Ding","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qi","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J","family":"Kim","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mensa","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2019123007075525000_CIT0001","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019123007075525000_CIT0002","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2019123007075525000_CIT0003","unstructured":"European AIDS Clinical Society. Guidelines. Version 9.1,2018. http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf. Accessed 5 June 2019."},{"key":"2019123007075525000_CIT0004","volume-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infect diagnosis of HIV,","author":"World Health Organization","year":"2018"},{"key":"2019123007075525000_CIT0005","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","author":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America: Hepatitis C Virus Guidance Panel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019123007075525000_CIT0006","doi-asserted-by":"crossref","first-page":"e02558","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019123007075525000_CIT0007","doi-asserted-by":"crossref","first-page":"e01620","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019123007075525000_CIT0008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019123007075525000_CIT0009","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"2019123007075525000_CIT0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"2019123007075525000_CIT0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"2019123007075525000_CIT0012","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019123007075525000_CIT0013","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2017","journal-title":"Hepatology"},{"key":"2019123007075525000_CIT0014","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"2019123007075525000_CIT0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"2019123007075525000_CIT0016","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"2019123007075525000_CIT0017","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019123007075525000_CIT0018","author":"Center for Drug Evaluation and Research","year":"2017"},{"key":"2019123007075525000_CIT0019","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.119.256966","article-title":"Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir","volume":"370","author":"Kosloski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2019123007075525000_CIT0020","volume-title":"Clinical drug interaction studies\u2014study design, data analysis, and clinical implications guidance for industry","author":"US","year":"2017"},{"key":"2019123007075525000_CIT0021","author":"US Department of Health and Human Services, National Institute of Health, National Cancer Institute","year":"2010"},{"key":"2019123007075525000_CIT0022","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1089\/apc.2013.0009","article-title":"Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up","volume":"27","author":"Laprise","year":"2013","journal-title":"AIDS Patient Care STDS"},{"key":"2019123007075525000_CIT0023","volume-title":"Reyataz\u00ae (atazanavir capsules)","author":"Bristol-Myers Squibb Company","year":"2018"},{"key":"2019123007075525000_CIT0024","volume-title":"Norvir (ritonavir tablets)","author":"AbbVie Inc","year":"2017"},{"key":"2019123007075525000_CIT0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"key":"2019123007075525000_CIT0026","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jcph.256","article-title":"Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin","volume":"54","author":"Custodio","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2019123007075525000_CIT0027","volume-title":"MavyretTM (glecaprevir and pibrentasvir tablets)","author":"AbbVie Inc","year":"2017"},{"key":"2019123007075525000_CIT0028","volume-title":"Maviret 100 mg\/40 mg film-coated tablets","author":"AbbVie Deutschland GmbH & Co. KG.","year":"2017"},{"key":"2019123007075525000_CIT0029","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/0091270004269142","article-title":"Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital","volume":"44","author":"Hariparsad","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"2019123007075525000_CIT0030","author":"US Food and Drug Administration"},{"key":"2019123007075525000_CIT0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":"Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"2019123007075525000_CIT0032","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2019123007075525000_CIT0033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1254\/jphs.08209FP","article-title":"Induction of multiple drug transporters by efavirenz","volume":"109","author":"Weiss","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"2019123007075525000_CIT0034","volume-title":"Edurant (rilpivirine) tablets for oral use","author":"Janssen Therapeutics","year":"2014"},{"key":"2019123007075525000_CIT0035","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/COH.0b013e328356e91c","article-title":"Pharmacology of HIV integrase inhibitors","volume":"7","author":"Adams","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"key":"2019123007075525000_CIT0036","first-page":"354908","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez-Fernandez","year":"2011","journal-title":"AIDS Res Treat"},{"key":"2019123007075525000_CIT0037","volume-title":"Biktarvy\u00ae (bictegravir, emtricitabine, and tenofovir alafenamide tablets)","author":"Gilead Sciences Inc","year":"2018"},{"key":"2019123007075525000_CIT0038","volume-title":"Vosevi\u00ae (sofosbuvir, velpatasvir, and voxilaprevir tablets)","author":"Gilead Sciences Inc","year":"2017"},{"key":"2019123007075525000_CIT0039","unstructured":"Zhang H , CustodioJM, WeiX, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir (abstract 40). In: Conference on Retroviruses and Opportunistic Infections. Seattle, Washington, 13\u201316 February 2017. http:\/\/www.croiconference.org\/sessions\/clinical-pharmacology-hiv-integrase-strand-transfer-inhibitor-bictegravir. Accessed 5 June 2019."},{"key":"2019123007075525000_CIT0040","unstructured":"Lutz J , ShaoY, LingJ, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide phase 3 exposure-response analysis of safety and efficacy in the treatment of HIV infection. In: 19th International Workshop on Clinical Pharmacology of Antiviral Therapy. Baltimore, MD, 22 May 2018. http:\/\/www.natap.org\/2018\/Pharm\/Pharm_14.htm. Accessed 5 June 2019."},{"key":"2019123007075525000_CIT0041","author":"University of Liverpool"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz439\/30145445\/jiz439.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/2\/223\/31634672\/jiz439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/221\/2\/223\/31634672\/jiz439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T15:16:20Z","timestamp":1664205380000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/221\/2\/223\/5556482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,29]]},"published-print":{"date-parts":[[2020,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz439","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,15]]},"published":{"date-parts":[[2019,8,29]]}}}